**Name of Journal: *World Journal of Clinical Oncology***

**ESPS Manuscript NO: 21234**

**Manuscript Type: Editorial**

**Present laparoscopic surgery for colorectal cancer in Japan**

Sato T *et al.* Present laparoscopic surgery for colorectal cancer in Japan

**Takeo Sato, Masahiko Watanabe**

**Takeo Sato, Masahiko Watanabe,** Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan

**Author contributions:** Sato T and Watanabe M contributed equally to this work; Sato T drafted the manuscript; Watanabe M made significant edits of intellectual content; Sato T and Watanabe M approved the overall works.

**Conflict-of-interest** **statement:** Sato T and Watanabe M declare they have no conflict of interest or financial ties.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Masahiko Watanabe, MD, PhD,** Department of Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan. intl-aff@kitasato-u.ac.jp

**Telephone:** +81-42-7788111

**Fax:** +81-42-7789556

**Received:** July 1, 2015

**Peer-review started:** July 7, 2015

**First decision:** September 22, 2015

**Revised:** October 19, 2015

**Accepted:** December 17, 2015

**Article in press:**

**Published online:**

**Abstract**

In many clinical studies, laparoscopic surgery (LS) for colon cancer has been shown to be less invasive than open surgery (OS) while maintaining similar safety. Furthermore, there are no significant differences between LS and OS in long-term outcomes. Thus, LS has been accepted as one of the standard treatments for colon cancer. In the treatments of rectal cancer as well, LS has achieved favorable outcomes, with many reports showing long-term outcomes comparable to those of OS. Furthermore, the magnification in laparoscopy improves visualization in the pelvic cavity and facilitates precise manipulation, as well as providing excellent educational effects. For these reasons, rectal cancer has seemed to be well indicated for LS, as has been colon cancer. The indication for LS in the treatment of locally advanced rectal cancer, which is relatively unresectable (*e.g.*, cancer invading other organs), remains an open issue. In recent years, new techniques such as single-port and robotic surgery have begun to be introduced for LS. Presently, various clinical studies in our country as well as in most Western countries have demonstrated that LS, with these new techniques, are gradually showing long-term outcomes.

**Key words:** Laparoscopic surgery; Colorectal cancer; Colectomy; Total mesorectal excision; Randomized controlled trial; Robotic surgery; Single-port surgery

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Our findings describe the merits of laparoscopic surgery (LS) over open surgery. We present some new LS techniques. We conclude with an explanation of the safety and curability of LS for colorectal cancer.

Sato T, Watanabe M. Present laparoscopic surgery for colorectal cancer in Japan. *World J Clin Oncol* 2015; In press

**INTRODUCTION**

Laparoscopic surgery (LS) for bowel disease was first reported in 1991 in the United States[1]. In Japan, the first such surgery was performed in 1992 for a patient with cecal cancer[2]. Subsequently, the indications for LS were gradually expanded to include colorectal cancer and inflammatory bowel diseases such as appendicitis and diverticulitis[3]. Around 1994, however, frequent port site recurrences (PSR) after LS for colon cancer were reported, resulting in LS temporarily being deemed to be contraindicated[4]. On the other hand, few reports on PSR were reported in Japan at that time. The reason LS had a very low incidence of PSR was that the indication of LS was limited to early stage cancer in Japan. PSR was, at that time, reported as arising from the spreading of cancer cells during LS due to inappropriate manipulations of the tumor. After this realization, the principles of surgical oncology were strictly followed resulting in decreased port site recurrence; and presently, there have been no such cases reported. As the use of LS spread, clinical studies began to be carried out comparing its short- and long-term outcomes with those of open surgery (OS)[5]. On the basis of these results, LS spread rapidly in Japan becoming another standard therapy for bowel diseases, in addition to the conventional OS. Herein, we outline the current status of LS for colorectal cancer in Japan and its perspectives for the future.

**COLON CANCER**

Regarding colon cancer, randomized controlled trials (RCTs) comparing LS with OS have been carried out, and numerous meta-analyses of data from such trials have been reported. These reports demonstrated the superiority of LS over OS in terms of short-term outcomes and the non-inferiority of LS to OS in terms of long-term outcomes. As LS has increasingly become a standard procedure, the difference in operative time versus OS has gradually been reduced. In Japan, a randomized controlled trial to confirm the non-inferiority of LS to OS in terms of overall survival was conducted. And the primary endpoint of 5-year overall survival was demonstrated in ASCO-GI 2014[6]. Eligibility criteria included: colon cancer; tumor located in the cecum, ascending, sigmoid, or recto-sigmoid colon; T3 or T4 without involvement of other organs; N0-2; and M0. Patients were randomized preoperatively and underwent tumor resection with D3 dissection. A total of 1057 patients were randomized (OP 528, LAP 529) from October 2004 through March 2009. Conversion to OS was only needed for 29 patients (5.4%) in the LS arm. The low conversion rate indicated a high quality of surgeons in this study group. JCOG0404 and results of other large clinical trials are shown in Table 1. The 5-year OS was 90.4% (95%CI: 87.5%-92.6%) in the OS arm, and 91.8% (95%CI: 89.1%-93.8%) in the LS arm. The non-inferiority of laparoscopic complete mesocolic excision in overall survival was not demonstrated[4]. Additionally, patients assigned to LS had less blood loss (*P* < 0.001), although LS lasted 52 min longer (*P* < 0.001). The short-term results in this trial are shown in Table 2. LS was associated with a shorter time to the first flatus, decreased use of analgesics after 5 postoperative days, and a shorter hospital stay. Morbidity [14.3% (76/533) *vs* 22.3% (117/524), *P* < 0.001) was lower in the LS arm[7]. Unfortunately, the non-inferiority of laparoscopic complete mesocolic excision in overall survival was not demonstrated for stage II, III colorectal cancer, however, because the overall survival of both arms was relatively identical and better than expected. Furthermore, the safety of LS in elderly patients and those with Stage IV disease, for whom less invasive surgery is desirable, has been demonstrated retrospectively, and another RCT is now underway[8,9]. Therefore, during the two decades since its initial introduction, data unique to Japan, serving as evidence for the validity of LS as a standard therapy for colon cancer, have steadily been accumulated.

**RECTAL CANCER**

Standard treatment procedures for advanced rectal cancer have yet to be established in most Western countries and Japan. Control of local recurrence, a characteristic of advanced rectal cancer, is an important treatment goal, along with the improvement of overall survival. Total mesorectal excision (TME) has been accepted as a standard procedure for the reduction of local recurrence throughout the world. As for the clinical significance of prophylactic lateral lymph node dissection, which is aggressively performed in Japan, patient enrollment in an RCT comparing this procedure with TME has been completed. The results of this trial are awaited.

Whether or not LS is an appropriate procedure for rectal cancer remains unclear. In many RCTs conducted in Western countries, LS is not indicated for the treatment of rectal cancer. The MRC (Medical Research Council) CLASIC trial, an RCT of patients with colorectal cancer, reported a higher rate of tumor-positive circumferential resection margins after LS, despite no significant differences in the local recurrence rate or overall survival rate compared to LS. Oncologic safety was therefore not demonstrated.

Numerous clinical research investigations including RCTs comparing LS and OS in patients with rectal cancer, and meta-analyses have been conducted in recent years. COLOR II (2004-2010) designed in the Netherlands and the COREAN trial (2006-2009) in South Korea exemplify RCTs focusing on advanced rectal cancer (cT3, T4)[10-13]. Both of these trials showed more significance of LS between groups in short-term outcome, and no significant differences were found in the complication rate. The long-term outcome of the CREAN trial reported no statistical differences in 3-year event-free survival rate at the primary end point, local recurrence rate at the secondary endpoint, overall survival rate, and quality of life. The same applies to the COLOR II trial targeting 1044 cases of rectal cancer, where no statistical significances were shown between the two groups in 3-year local recurrence rate at the primary end point, and overall survival rate and event-free survival rate at the secondary end point.

In Japan, phase II studies are being performed to evaluate the safety and effectiveness of LS for clinical Stage 0/I lower rectal cancer. As the first step, studies were designed to assess the technical safety of LS. The primary endpoint was the incidence of adverse events. If the safety is confirmed, the second step will focus on oncologic outcomes, with overall survival as the primary endpoint. Secondary endpoints in both the first and second steps included recurrence-free survival, operative mortality, the rate of histologically curative surgery, and the rate of conversion to OS. The results of these clinical studies are very important for determining the future indications of LS for rectal cancer.

**CERTIFICATION SYSTEM FOR SURGEONS**

In 2005, the Japan Society for Endoscopic Surgery began a certification system for the fields of gastrointestinal and general surgery. This certification system initially focused on surgical technique. Accreditation in the fields of gastrointestinal and general surgery required experience as the head surgeon or an instructive assistant in at least 20 advanced operations, as well as the ability to independently perform advanced endoscopic surgery in a specialized field, and to provide “procedural guidance” on technique. Along with having the technical skills of a head surgeon, certification required that the candidate could act as a coordinator of LS. Certification is also based on a detailed review of unedited videotapes of the candidates’ LSs. About 20%-40% of the applicants who apply receive accreditation. Review criteria are made public, and all reviews are conducted on an impartial basis.

***Minimal invasiveness of laparoscopic colectomy***

Compared with OS, LS offers many benefits, such as a small surgical wound, good esthetic results, less pain, decreased use of analgesics, early recovery of intestinal peristalsis, and a shorter hospital stay[14-23]. In terms of inflammatory cytokine levels, however, the minimal invasiveness of LS remains controversial. Some studies have reported significantly lower inflammatory cytokine levels after LS[15,16], whereas others have found no significant difference in such levels between LS and OS[17,24,25]. Further studies are needed to objectively evaluate the minimal invasiveness of LS for colorectal cancer.

**NEW OPERATIVE TECHNIQUES**

New laparoscopic procedures such as natural orifice specimen extraction (NOSE ), single-port surgery, and robotic surgery have begun to be attempted for colorectal cancer as well as other diseases covered by endoscopic surgery[26-28]. Regarding NOSE for colorectal disease, a procedure involving removal of the resected bowel via the vagina or anus has frequently been reported. The procedure performed via the vagina is applicable to all bowel resection techniques including right hemicolectomy, but the procedure via the anus is applicable only to resection of rectal cancers located at low levels. NOSE requires resection and anastomosis within the peritoneal cavity and is therefore more difficult and time-consuming than LS. In terms of short-term outcomes (*e.g*., safety), it has been reported that NOSE is not inferior to LS. However, despite the complex manipulations required, the only significant advantage of NOSE is the esthetic outcome, according to the data collected to date.

In Japan, robotic surgery for colorectal cancer is not covered by the national health insurance, so patients receiving this surgery must pay all the related hospital expenses themselves. During robotic surgery, the surgeon remotely controls the robot three-dimensionally from a console, with the use of a binocular magnifier. Physiological tremor of the surgeon is erased electronically through the automation of the robot. The three-dimensional visual field and the manipulation of the forceps with a high degree of freedom can evidently shorten the learning curve for surgeons. However, a large-scale system is needed, preoperative manipulations are complex, and the devices and materials are expensive. Robotic surgery has been reported to be excellent as a means of preserving nerves during pelvic surgery and improving the precision of total mesenteric resection. On the other hand, smoothly dealing with accidental events during surgery (*e.g.*, bleeding) is anticipated to be difficult because this surgery requires such a large-scale system. Therefore, it would be desirable to clarify the features if in which robotic surgery is superior to LS.

**CONCLUSION**

The colon and rectum are rich in elasticity, and their resection and anastomosis are possible, leaving only a small surgical wound and enabling segments to easily be exposed for surgery. The visual field magnification of a laparoscopy allows high precision surgery in the narrow pelvic cavity. The colon and rectum can, therefore, be regarded as organs suitable for LS. If further efforts are made to achieve standardization of LS procedures and improvement of the LS educational system, LS will undoubtedly become a standard therapy for many bowel diseases. Furthermore, it is anticipated that new techniques such as reduced port surgery and robotic surgery will be proven safe in the near future. In any event, it is desirable to develop and advance operative procedures favorable from the viewpoints of low invasiveness, high safety, radical treatment capability, and cost effectiveness.

In Japan, the safety and curability of surgery for colorectal cancer are much better than in most Western countries, facilitating the rapid expansion of LS. LS is expected to gain further acceptance and progress even farther. However, daily efforts of colorectal surgeons to improve their surgical skills and to continuously collect and analyze data are considered most important.

**REFERENCES**

1 **Jacobs M**, Verdeja JC, Goldstein HS. Minimally invasive colon resection (laparoscopic colectomy). *Surg Laparosc Endosc* 1991; **1**: 144-150 [PMID: 1688289]

2 **Watanabe M**, Ohgami M, Teramoto T, Kitajima M. Laparoscopic local excision of the cecum for cecal creeping tumor. *Surg Laparosc Endosc* 1997; **7**: 144-147 [PMID: 9109246 DOI: 10.1097/00019509-199704000-00016]

3 **Maggiori L**, Panis Y. Surgical management of IBD--from an open to a laparoscopic approach. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 297-306 [PMID: 23419288 DOI: 10.1038/nrgastro.2013.30]

4 **Zmora O**, Gervaz P, Wexner SD. Trocar site recurrence in laparoscopic surgery for colorectal cancer. *Surg Endosc* 2001; **15**: 788-793 [PMID: 11443452 DOI: 10.1007/s004640080151]

5 **Theophilus M**, Platell C, Spilsbury K. Long-term survival following laparoscopic and open colectomy for colon cancer: a meta-analysis of randomized controlled trials. *Colorectal Dis* 2014; **16**: O75-O81 [PMID: 24206016 DOI: 10.1111/codi.12483]

6 **Inomata M**, Katayama H, Mizusawa J. A randomized controlled trial to evaluate laparoscopic versus open complete mesocolic excision (CME) for stage II, III colorectal cancer (CRC): First efficacy results from Japan Clinical Oncology Group Study JCOG0404. *J Clin Oncol* 2015; **33** (Suppl 3): Abstract No. 656

7 **Yamamoto S**, Inomata M, Katayama H, Mizusawa J, Etoh T, Konishi F, Sugihara K, Watanabe M, Moriya Y, Kitano S. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. *Ann Surg* 2014; **260**: 23-30 [PMID: 24509190 DOI: 10.1097/SLA.0000000000000499]

8 **Hinoi T**, Kawaguchi Y, Hattori M, Okajima M, Ohdan H, Yamamoto S, Hasegawa H, Horie H, Murata K, Yamaguchi S, Sugihara K, Watanabe M. Laparoscopic versus open surgery for colorectal cancer in elderly patients: a multicenter matched case-control study. *Ann Surg Oncol* 2015; **22**: 2040-2050 [PMID: 25331007 DOI: 10.1245/s10434-014-4172-x]

9 **Hida K**, Hasegawa S, Kinjo Y, Yoshimura K, Inomata M, Ito M, Fukunaga Y, Kanazawa A, Idani H, Sakai Y, Watanabe M. Open versus laparoscopic resection of primary tumor for incurable stage IV colorectal cancer: a large multicenter consecutive patients cohort study. *Ann Surg* 2012; **255**: 929-934 [PMID: 22367445 DOI: 10.1097/SLA.0b013e31824a99e4]

10 **van der Pas MH**, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol* 2013; **14**: 210-218 [PMID: 23395398 DOI: 10.1016/S1470-2045(13)70016-0]

11 **Bonjer HJ**, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA, Andersson J, Angenete E, Rosenberg J, Fuerst A, Haglind E. A randomized trial of laparoscopic versus open surgery for rectal cancer. *N Engl J Med* 2015; **372**: 1324-1332 [PMID: 25830422 DOI: 10.1056/NEJMoa1414882]

12 **Kang SB**, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. *Lancet Oncol* 2010; **11**: 637-645 [PMID: 20610322 DOI: 10.1016/S1470-2045(10)70131-5]

13 **Jeong SY**, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. *Lancet Oncol* 2014; **15**: 767-774 [PMID: 24837215 DOI: 10.1016/S1470-2045(14)70205-0]

14 **Thaler K**, Weiss EG, Nogueras JJ, Arnaud JP, Wexner SD, Bergamaschi R. Recurrence rates at minimum 5-year follow-up: laparoscopic versus open sigmoid resection for uncomplicated diverticulitis. *Surg Laparosc Endosc Percutan Tech* 2003; **13**: 325-327 [PMID: 14571169 DOI: 10.1097/00129689-200310000-00008]

15 **Lawrence DM**, Pasquale MD, Wasser TE. Laparoscopic versus open sigmoid colectomy for diverticulitis. *Am Surg* 2003; **69**: 499-503; discussion 503-504 [PMID: 12852507]

16 **Menenakos E**, Hahnloser D, Nassiopoulos K, Chanson C, Sinclair V, Petropoulos P. Laparoscopic surgery for fistulas that complicate diverticular disease. *Langenbecks Arch Surg* 2003; **388**: 189-193 [PMID: 12836027 DOI: 10.1007/s00423-003-0392-4]

17 **Le Moine MC**, Fabre JM, Vacher C, Navarro F, Picot MC, Domergue J. Factors and consequences of conversion in laparoscopic sigmoidectomy for diverticular disease. *Br J Surg* 2003; **90**: 232-236 [PMID: 12555302 DOI: 10.1002/bjs.4035]

18 **Dwivedi A**, Chahin F, Agrawal S, Chau WY, Tootla A, Tootla F, Silva YJ. Laparoscopic colectomy vs. open colectomy for sigmoid diverticular disease. *Dis Colon Rectum* 2002; **45**: 1309-1314; discussion 1309-1314 [PMID: 12394427 DOI: 10.1007/s10350-004-6415-6]

19 **Senagore AJ**, Duepree HJ, Delaney CP, Dissanaike S, Brady KM, Fazio VW. Cost structure of laparoscopic and open sigmoid colectomy for diverticular disease: similarities and differences. *Dis Colon Rectum* 2002; **45**: 485-490 [PMID: 12006930 DOI: 10.1007/s10350-004-6225-x]

20 **Bouillot JL**, Berthou JC, Champault G, Meyer C, Arnaud JP, Samama G, Collet D, Bressler P, Gainant A, Delaitre B. Elective laparoscopic colonic resection for diverticular disease: results of a multicenter study in 179 patients. *Surg Endosc* 2002; **16**: 1320-1323 [PMID: 11984674 DOI: 10.1007/s00464-001-9236-x]

21 **Tuech JJ**, Regenet N, Hennekinne S, Pessaux P, Bergamaschi R, Arnaud JP. Laparoscopic colectomy for sigmoid diverticulitis in obese and nonobese patients: a prospective comparative study. *Surg Endosc* 2001; **15**: 1427-1430 [PMID: 11965459 DOI: 10.1007/s00464-001-9023-8]

22 **Trebuchet G**, Lechaux D, Lecalve JL. Laparoscopic left colon resection for diverticular disease. *Surg Endosc* 2002; **16**: 18-21 [PMID: 11961597 DOI: 10.1007/s004640090122]

23 **Tuech JJ**, Pessaux P, Regenet N, Rouge C, Hennekinne S, Bergamaschi R, Arnaud JP. Laparoscopic colectomy for sigmoid diverticulitis: a prospective study in the elderly. *Hepatogastroenterology* 2001; **48**: 1045-1047 [PMID: 11490796]

24 **Bergamaschi R**, Tuetch JJ, Pessaux P, Arnaud JP. Intracorporeal vs laparoscopic-assisted resection for uncomplicated diverticulitis of the sigmoid. *Surg Endosc* 2000; **14**: 520-523 [PMID: 10890956 DOI: 10.1007/s004640000094]

25 **Bergamaschi R**, Tuech JJ, Cervi C, Arnaud JP. Re-establish pneumoperitoneum in laparoscopic-assisted sigmoid resection? Randomized trial. *Dis Colon Rectum* 2000; **43**: 771-774 [PMID: 10859075 DOI: 10.1007/BF02238012]

26 **Kim HJ**, Choi GS, Park JS, Park SY, Ryuk JP, Yoon SH. Transvaginal specimen extraction versus conventional minilaparotomy after laparoscopic anterior resection for colorectal cancer: mid-term results of a case-matched study. *Surg Endosc* 2014; **28**: 2342-2348 [PMID: 24566749 DOI: 10.1007/s00464-014-3466-1]

27 **Hua J**, Gong J, Xu B, Yang T, Song Z. Single-incision versus conventional laparoscopic appendectomy: a meta-analysis of randomized controlled trials. *J Gastrointest Surg* 2014; **18**: 426-436 [PMID: 24002764 DOI: 10.1007/s11605-013-2328-9]

28 **Zarak A**, Castillo A, Kichler K, de la Cruz L, Tamariz L, Kaza S. Robotic versus laparoscopic surgery for colonic disease: a meta-analysis of postoperative variables. *Surg Endosc* 2015; **29**: 1341-1347 [PMID: 25847139 DOI: 10.1007/s00464-015-4197-7]

**P-Reviewer:** Golffier C, Surlin V, Ji W **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Trial JCOG0404 and other large clinical trials**

|  |  |  |  |
| --- | --- | --- | --- |
| **Trials** | **Cases****Open:Laparoscopy** | **Conversion rate (%)** | **Overall survival (%)****Open:Laparoscopy** |
| **COST** | **428:435** | **21** | **85:86** |
| **Braga** | **201:190** | **4** | **83:84** |
| **CLASIC C** | **268:526** | **16** | **68:67** |
| **COLOR** | **621:627** | **19** | **84.2:81.8** |
| **JCOG 0404** | **533:524** | **29 cases****5.4%** | **> 90** |

**Table 2 Short-term results in the JCOG0404 trial**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Laparoscopic surgery** | **Open surgery** | ***P* value** |
| **Bleeding (mL)** | **50** | **85** | **< 0.001** |
| **Operation time (min)** | **211** | **159** | **< 0.001** |
| **Lymph node dissections** | **=** | **Not significant** |
| **First postoperative flatus**  | **<** |  |
| **Postoperative hospital stay** | **<** |  |
| **Surgical site infection (superficial layer)** | **<** |  |
| **Complications****(anastomosis leakage/ileus)** | **＝** |  |